Ⅰ型干扰素在狼疮性肾炎中的致病作用及其靶向治疗的研究进展

Research progress on the pathogenicity and targeted therapy efficacy of typeⅠinterferon in lupus nephritis

狼疮性肾炎(lupus nephritis,LN)是系统性红斑狼疮常见的严重并发症之一,与预后及死亡率相关。许多证据表明,Ⅰ型干扰素(typeⅠinterferon,IFN-Ⅰ)作为抗病毒、抗肿瘤及调节先天性和适应性免疫功能的重要分子,在LN患者肾脏中表达增加,直接损伤肾组织或间接增强免疫应答,介导LN的发生、发展。在最近的研究中,IFN-Ⅰ受体抗体Anifrolumab在LN患者中初步获得了较佳的肾脏结局,表明这可能是一种延缓LN肾脏进展新的方向,将会推动未来相关靶向治疗的发展。

Lupus nephritis(LN)is one of the common severe complications of systemic lupus erythematosus and is related to prognosis and mortality of this disease.TypeⅠinterferon(IFN-Ⅰ)is an important molecule for antiviral,anti-tumor,and regulating innate and adaptive immune functions.Many evidences show that IFN-Ⅰexpression increases in the kidney of patients with LN,which directly damages the renal tissue or indirectly enhances the immune response,and mediates the occurrence and development of LN.In recent studies,the antibody of typeⅠinterferon receptor anifrolumab has initially achieved a better renal outcome in LN patients,indicating that this may be a new direction to delay the progress of LN,and will promote the development of relevant targeted therapy in the future.